In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Akebia Therapeutics Inc. (NASDAQ: AKBA) closed at $1.59 in the last session, down -3.05% from day before closing price of $1.64. In other words, the price has decreased by -$3.05 from its previous closing price. On the day, 3.03 million shares were traded. AKBA stock price reached its highest trading level at $1.69 during the session, while it also had its lowest trading level at $1.54.
Ratios:
We take a closer look at AKBA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 1.04.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 13 ’24 when Hadas Nicole R. sold 12,016 shares for $1.26 per share. The transaction valued at 15,140 led to the insider holds 651,243 shares of the business.
Dahan Michel sold 34,840 shares of AKBA for $43,898 on May 13 ’24. The SVP, Chief Operating Officer now owns 672,092 shares after completing the transaction at $1.26 per share. On Feb 29 ’24, another insider, Dahan Michel, who serves as the SVP, Chief Operating Officer of the company, sold 8,661 shares for $1.58 each. As a result, the insider received 13,684 and left with 706,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 344872576 and an Enterprise Value of 399482240. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.92. Its current Enterprise Value per Revenue stands at 2.289 whereas that against EBITDA is 97.888.
Stock Price History:
Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.78. The 50-Day Moving Average of the stock is 13.68%, while the 200-Day Moving Average is calculated to be 14.95%.
Shares Statistics:
According to the various share statistics, AKBA traded on average about 1.66M shares per day over the past 3-months and 1694290 shares per day over the past 10 days. A total of 210.29M shares are outstanding, with a floating share count of 199.72M. Insiders hold about 5.03% of the company’s shares, while institutions hold 24.20% stake in the company. Shares short for AKBA as of 1727654400 were 18803189 with a Short Ratio of 11.34, compared to 1724976000 on 19067933. Therefore, it implies a Short% of Shares Outstanding of 18803189 and a Short% of Float of 9.04.
